Literature DB >> 8039906

Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis.

S Pal1, T J Fielder, E M Peterson, L M de la Maza.   

Abstract

Female BALB/c mice were immunized intranasally with the mouse pneumonitis biovar of Chlamydia trachomatis and subsequently challenged in the ovarian bursa (C. trachomatis immunized, C. trachomatis challenged). Two groups of mice served as controls. One group was sham immunized intranasally with mock-infected HeLa 229 cell extracts and was challenged in the ovarian bursa with C. trachomatis MoPn (sham immunized, C. trachomatis challenged). The second control group was sham immunized and not challenged (sham immunized, nonchallenged). Before challenge, the C. trachomatis-immunized, C. trachomatis-challenged animals mounted a significant humoral response as shown by high immunoglobulin G (IgG), IgM, and IgA levels and high levels of neutralizing antibodies in serum and moderate IgG and IgA titers in vaginal secretions. Reactivity by Western blot (immunoblot) to the lipopolysaccharide, 30-, 40- (major outer membrane protein), and 60-kDa cysteine-rich proteins and 75- and 100-kDa chlamydial components could be demonstrated. However, reactivity to the 60-kDa heat shock protein was only observed 22 days after challenge. In addition, this group of animals mounted a significant immune response to chlamydial antigens, as shown by a lymphocyte proliferation assay, compared with the sham-immunized nonchallenged mice. After intrabursal challenge, there was no C. trachomatis shedding from the vagina in the C. trachomatis-immunized, C. trachomatis-challenged animals, while 63% of the sham-immunized, C. trachomatis-challenged mice had a positive C. trachomatis culture. In addition, histological sections from the genital tract showed, at 2 weeks postchallenge, a marked acute inflammatory reaction in the sham-immunized, C. trachomatis-challenged animals while in the C. trachomatis-immunized, C. trachomatis-challenged mice there was minimal inflammatory reaction. When the animals were mated, only 12% of the mice from the sham-immunized, C. trachomatis-challenged mice were fertile. In contrast, 94 and 80% of the sham-immunized, nonchallenged and C. trachomatis-immunized, C. trachomatis-challenged mice, respectively, were fertile.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8039906      PMCID: PMC302966          DOI: 10.1128/iai.62.8.3354-3362.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  47 in total

Review 1.  Chlamydial vaccines--future trends.

Authors:  M E Ward
Journal:  J Infect       Date:  1992-07       Impact factor: 6.072

Review 2.  Introduction: objectives of herpes simplex virus vaccines seen from a historical perspective.

Authors:  B Roizman
Journal:  Rev Infect Dis       Date:  1991 Nov-Dec

3.  Chlamydia trachomatis-associated ectopic pregnancy: serologic and histologic correlates.

Authors:  R C Brunham; R Peeling; I Maclean; M L Kosseim; M Paraskevas
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

4.  Endocervical chlamydial deoxyribonucleic acid in infertile women.

Authors:  Y K Soong; S M Kao; C J Lee; P S Lee; C C Pao
Journal:  Fertil Steril       Date:  1990-11       Impact factor: 7.329

5.  Antibody responses to the chlamydial heat shock proteins hsp60 and hsp70 are H-2 linked.

Authors:  G Zhong; R C Brunham
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

6.  A single peptide from the major outer membrane protein of Chlamydia trachomatis elicits T cell help for the production of antibodies to protective determinants.

Authors:  J E Allen; R M Locksley; R S Stephens
Journal:  J Immunol       Date:  1991-07-15       Impact factor: 5.422

7.  Resolution of chlamydial genital infection with antigen-specific T-lymphocyte lines.

Authors:  K H Ramsey; R G Rank
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

8.  Analysis of the human serological response to Chlamydia trachomatis 60-kDa proteins by two-dimensional electrophoresis and immunoblotting.

Authors:  A M Coles; H A Crosby; J H Pearce
Journal:  FEMS Microbiol Lett       Date:  1991-07-01       Impact factor: 2.742

9.  Role of L3T4-bearing T-cell populations in experimental murine chlamydial salpingitis.

Authors:  D V Landers; K Erlich; M Sung; J Schachter
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

View more
  57 in total

1.  A new murine model for testing vaccines against genital Chlamydia trachomatis infections in males.

Authors:  Sukumar Pal; Annahita K Sarcon; Luis M de la Maza
Journal:  Vaccine       Date:  2010-10-13       Impact factor: 3.641

2.  A murine model for the study of Chlamydia trachomatis genital infections during pregnancy.

Authors:  S Pal; E M Peterson; L M De La Maza
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Immunization with a peptide corresponding to chlamydial heat shock protein 60 increases the humoral immune response in C3H mice to a peptide representing variable domain 4 of the major outer membrane protein of Chlamydia trachomatis.

Authors:  V L Motin; L M de la Maza; E M Peterson
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

Review 4.  Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.

Authors:  Christina M Farris; Richard P Morrison
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

5.  Susceptibility of mice to vaginal infection with Chlamydia trachomatis mouse pneumonitis is dependent on the age of the animal.

Authors:  S Pal; E M Peterson; L M de la Maza
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

6.  Vaccination with major outer membrane protein proteosomes elicits protection in mice against a Chlamydia respiratory challenge.

Authors:  Delia F Tifrea; Sukumar Pal; Deana N Toussi; Paola Massari; Luis M de la Maza
Journal:  Microbes Infect       Date:  2013-08-30       Impact factor: 2.700

7.  Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization.

Authors:  Pooja Ralli-Jain; Delia Tifrea; Chunmei Cheng; Sukumar Pal; Luis M de la Maza
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

8.  Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.

Authors:  Delia F Tifrea; Sukumar Pal; Jean-Luc Popot; Melanie J Cocco; Luis M de la Maza
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

9.  Route of infection that induces a high intensity of gamma interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice.

Authors:  J U Igietseme; I M Uriri; S N Kumar; G A Ananaba; O O Ojior; I A Momodu; D H Candal; C M Black
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

10.  Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.

Authors:  Guifeng Sun; Sukumar Pal; Joseph Weiland; Ellena M Peterson; Luis M de la Maza
Journal:  Vaccine       Date:  2009-05-27       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.